Name (Synonyms) | Correlation | |
---|---|---|
drug1007 | Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed Wiki | 1.00 |
drug2432 | TOF protocol Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Pragmatic randomized clinical trial of patients admitted to the hospital with confirmed COVID-19 infection and elevated D-Dimer. Randomization 1:1 - Group 1 will undergo a routine full anticoagulation (oral or parenteral when needed) strategy; and group 2 will receive usual standard of care with prophylactic anticoagulation
Description: The primary objective will be analyzed using the win ratio approach comparing every participant of treatment group to every participant of control group to determine a winner.
Measure: Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days. Time: In 30 daysDescription: It will be considered the main safety endpoint
Measure: Incidence of Major bleeding and clinically relevant non-major bleeding by the ISTH criteria Time: In 30 days